Product category:
Proteomics
News Release from: Perkin Elmer LAS (UK) | Subject: Bioxpression
Edited by the Laboratorytalk Editorial
Team on 08 June 2005
Platform for biomarker discovery and
screening
Biomarker discovery and screening platform introduces proteomic signature technology that delivers high throughput and ultra-high mass accuracy and stability for high-confidence proteomic signatures
PerkinElmer has announced the launch of its Bioxpression biomarker discovery and screening platform at the 53rd American Society for Mass Spectrometry (ASMS) conference in San Antonio, Texas It says the platform provides a complete solution that can speed the discovery of biomarkers through its unique biomarker sample enrichment technology and highly accurate mass pattern recognition approach
This article was originally published on Laboratorytalk on 19 Apr 2002 at 8.00am (UK)
Related stories
Probing the source of diabetes
Newly developed gene probes increase efficiency and speed of research in studies of type 1 (juvenile) diabetes, detecting the presence of alleles by hybridisation reaction
Manage the entire gene expression process
With microarray labs generating more than one million primary data points daily, this gene expression data management software could speed up actual gene and drug discovery
The Bioxpression platform introduces new proteomic signature technology (PST) that delivers high throughput and ultra-high mass accuracy and stability, resulting in comprehensive and high-confidence proteomic signatures.
"Using advanced, innovative technologies, PerkinElmer has developed a suite of tools that provides the maximum meaningful data from multiple samples, improving confidence in results and reproducibility," said Peter Coggins, president of PerkinElmer Life and Analytical Sciences.
"This comprehensive platform extends our well-established leadership in biomarker discovery and screening technology".
The Bioxpression biomarker platform includes the Protof 2000 Maldi-Tof mass spectrometer, Proxpression carrier protein-based blood biomarker enrichment kits, and Bamf technology from Predictive Diagnostics.
Two new components, a Maldi calibration kit and a standardisation kit, which will provide uniformity across multiple instrument platforms, were also launched at the show.
Recently, PerkinElmer and Predictive Diagnostics used the Bioxpression biomarker platform to identify a series of biomarkers that appear to differ in persons with Alzheimer's Disease compared to persons without cognitive impairment.
The study is the first of its kind to describe a potential diagnostic blood test for Alzheimer's disease.
• Perkin Elmer LAS (UK): contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
